

1           **Diagnosing diastolic dysfunction using explainable advanced electrocardiography**

2

3           Hayden McColl\*<sup>1,2</sup>, Sabbab Chowdhury\*<sup>1,3</sup>, Todd T Schlegel<sup>4,5</sup>, Maren Maanja<sup>4</sup>,

4           Kevin Yang<sup>1,3</sup>, Thomas Lindow<sup>1,6</sup>, Michelle Price<sup>7</sup>, Elias Fulthorp<sup>7</sup>, Sean Lal<sup>2,3,7</sup>,

5                           Michele McGrady<sup>2,7</sup>, Rebecca Kozor<sup>1</sup>, Martin Ugander<sup>1,3,4</sup>

6    \*Denotes equal contribution

7

8    <sup>1</sup>Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia

9    <sup>2</sup>Royal Prince Alfred Hospital, Sydney, Australia

10   <sup>3</sup>University of New South Wales, Sydney, Australia

11   <sup>4</sup>Department of Clinical Physiology, Karolinska University Hospital, and Karolinska

12   Institutet, Stockholm, Sweden

13   <sup>5</sup>Nicollier-Schlegel SARL, Trelex, Switzerland

14   <sup>6</sup>Clinical Physiology, Clinical Sciences, Lund University, Lund, Sweden

15   <sup>7</sup>Central Sydney Cardiology, Sydney, New South Wales

16   **Corresponding Address:**

17   Martin Ugander, MD, PhD  
18   Professor of Cardiac Imaging, University of Sydney  
19   Kolling Building, Level 12, Room 612017  
20   Royal North Shore Hospital  
21   St Leonards, Sydney NSW 2065  
22   Australia  
23   martin.ugander@gmail.com  
24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1    **Abstract**

2    **BACKGROUND AND AIMS:** Diastolic dysfunction of the left ventricle is a precursor to  
3    heart failure with preserved ejection fraction (HFpEF). Detection by electrocardiography  
4    (ECG) when asymptomatic (stage B heart failure) would be valuable. We hypothesised that  
5    an explainable advanced ECG (A-ECG) score derived from standard 12-lead ECG could  
6    accurately diagnose diastolic dysfunction.

7    **METHODS:** Included patients had undergone resting 12-lead ECG and echocardiography  
8    demonstrating normal systolic function, with at most mild valve disease, and either the  
9    presence (n=150) or absence (n=264) of grade II or III diastolic dysfunction. Stepwise  
10   multivariable logistic regression was used to generate an A-ECG score that was cross-  
11   validated using bootstrapping.

12   **RESULTS:** A 6-measure A-ECG score was able to identify diastolic dysfunction with an area  
13   under the receiver operating characteristics curve [95% confidence interval] of 0.91 [0.88-  
14   0.94], sensitivity 83 [76-91]%, specificity 87 [77-92]%, positive predictive value 78 [69-  
15   85]%, negative predictive value 90 [86-94]%, positive likelihood ratio 6.38 [3.30-11.38] and  
16   inverse negative likelihood ratio 5.12 [3.21-10.22].

17   **CONCLUSIONS:** Standard 12-lead ECG can be used to accurately identify diastolic  
18   dysfunction by echocardiography via A-ECG. This may have clinical utility for early  
19   identification of patients who may benefit from further cardiac assessment and risk factor  
20   management to prevent progression to symptomatic heart failure.

21

22

## 1 Introduction

2 Left ventricular (LV) diastolic dysfunction describes abnormalities in myocardial  
3 relaxation, compliance, and filling, thereby increasing the risk of developing heart failure with  
4 preserved ejection fraction (HFpEF)<sup>1, 2</sup>. Diastolic dysfunction may be initially asymptomatic  
5 (stage 2 heart failure) before progressing to symptomatic HFpEF (stage C and D), and may be  
6 present for many years before manifesting as overt heart failure<sup>3, 4</sup>. Aggressive management  
7 of cardiovascular risk factors including hypertension, diabetes and obesity has been shown to  
8 prevent or reduce disease progression<sup>5</sup>. Due to diastolic dysfunction commonly being  
9 asymptomatic before manifesting as HFpEF, earlier identification to better enable risk factor  
10 modification is desirable.

11 Diastolic dysfunction is most commonly assessed using transthoracic  
12 echocardiography. However, echocardiographic screening is not feasible on a population  
13 scale due to resource-related constraints<sup>6</sup>. As such, a low-cost screening method for diastolic  
14 dysfunction would be clinically valuable.

15 Attempts to use variations of the electrocardiogram (ECG) as a screening tool for  
16 diastolic dysfunction have shown promise. However, previous studies have relied heavily  
17 upon clinical data beyond the ECG or included methods that are difficult to implement on a  
18 largescale due to requirements for dedicated hardware that may not be widely available<sup>7, 8</sup>.

19 Advanced electrocardiography (A-ECG) is a term describing the application of  
20 multivariable statistics to a large number of measures obtained from a combination of analysis  
21 methods applied to the standard resting 12-lead ECG<sup>9, 10</sup>. Notably, A-ECG analysis can be  
22 performed on the raw digital ECG data recordings stored by any modern ECG vendor. A-  
23 ECG analysis on standard 10-sec ECGs enables improved diagnostic performance by  
24 incorporating not only conventional ECG measurements such as waveform amplitudes, axes  
25 and durations, but also measures of derived three-dimensional vectorcardiography (VCG) and

1 waveform complexity via singular value decomposition.<sup>10-12</sup>. A-ECG has been able to  
2 discriminate between health and disease in several conditions such as coronary artery disease,  
3 cardiomyopathy, LV hypertrophy and LV systolic dysfunction, with notably higher diagnostic  
4 accuracy compared to conventional ECG<sup>10, 13, 14</sup>. However, there have not yet been studies  
5 examining the utility of A-ECG in the diagnosis and screening of diastolic dysfunction. A-  
6 ECG may have use for screening at-risk, asymptomatic patients for diastolic dysfunction in  
7 the setting of constrained resources. Such patients might benefit from further investigation  
8 and aggressive risk factor management to prevent progression of disease to HFpEF and  
9 reduce its globally increasing burden.

10 Therefore, the aim of this study was to test the utility of an A-ECG scoring system for  
11 the diagnosis of diastolic dysfunction derived from a resting 12-lead ECG. We hypothesised  
12 that combined measures of A-ECG derived from the standard resting 12-lead ECG could be  
13 used to accurately identify the presence of diastolic dysfunction.

14

## 15 **Methods**

### 16 **Study Design**

17 This was a single-centre retrospective study of A-ECG in patients with diastolic  
18 dysfunction versus those with normal diastolic function as determined by transthoracic  
19 echocardiography (TTE). The study included patients who were referred for assessment at a  
20 large academic outpatient cardiology practice between January, 2018 and March, 2022. The  
21 study received ethics approval from the Sydney Local Health District Ethics Board (X19-  
22 0286 & 2019/ETH12064) as well as the respective human research ethics committee of the  
23 participating centre, with a retrospective waiver of informed consent.

24 Study inclusion criteria were age >50 years, sinus rhythm, left ventricular ejection  
25 fraction (LVEF)  $\geq 55\%$  and a recorded 12-lead ECG within 1 month of echocardiography.

1 Patients were excluded if they had moderate or greater valvular disease, LVEF <55%,  
2 hypertrophic cardiomyopathy, previous valvular replacement, coronary artery bypass surgery,  
3 or any other cardiac procedures that had required entering the pericardium. Exclusion criteria  
4 were ECG abnormalities that would limit A-ECG analysis such as atrial arrhythmias,  
5 predominant ventricular ectopic beats or QRS duration >110ms.

6 Echocardiographic examinations were evaluated and patients classified as having  
7 either normal or abnormal diastolic function. Abnormal diastolic dysfunction was defined as  
8 meeting criteria for either grade 2 or 3 diastolic dysfunction per the 2016 American Society of  
9 Echocardiography (ASE) assessment of diastolic dysfunction guidelines. Normal diastolic  
10 function was defined as the absence of any required criteria<sup>3</sup>. The patient inclusion flowchart  
11 is presented in detail in Figure 1.

## 12 **Advanced electrocardiography analysis**

13 All ECG recordings were performed by a commercial ECG system that acquired a  
14 resting 12-lead ECG of 10 second duration (Mortara Instruments Inc., USA). A-ECG analysis  
15 and its extensive methods have been detailed previously<sup>10, 15</sup>. In brief, conventional ECG  
16 parameters, including all major waveform intervals, axes, and voltages were derived  
17 automatically from the ECG recording software. A-ECG parameters were obtained after  
18 signal averaging the full ECG recordings using the in-house developed software<sup>10, 12,</sup>  
19 <sup>15</sup>. Derived -VCG measures were obtained from the 12-lead ECG using Kors' regression  
20 transformation<sup>16</sup>. QRS and T wave complexity was measured after signal averaging by using  
21 singular value decomposition<sup>10, 15</sup>.

22 An electrocardiographic heart age can also be estimated from 10-second 12-lead ECG  
23 recordings through use of A-ECG<sup>10</sup>. A person's heart age and related heart age gap (the  
24 AECG heart age minus chronological age) reflect a person's cardiovascular risk profile based  
25 on a range of ECG changes, expressed in units of years of healthy human ageing. AECG

1 Heart age and heart age gap were therefore calculated from the ECG for all patients in our  
2 cohort using a previously described A-ECG method<sup>10</sup>. Moreover, the likelihood of having left  
3 ventricular systolic dysfunction was also determined from the resting 12-lead ECG by using  
4 previously described A-ECG methods<sup>9</sup>.

## 5 **Statistical Analysis**

6 Statistical analyses including feature selection procedures were conducted using R  
7 version 4.2.0 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria) with  
8 packages dplyr for data transformation and ggplot2 for data visualisation, and SAS JMP  
9 version 11.0 (Cary, NC, USA)<sup>17, 18</sup>. Continuous variables are presented as mean ± standard  
10 deviation or median [interquartile range], as appropriate. Standard stepwise logistic regression  
11 was used to derive multivariable A-ECG scores for assessing diastolic dysfunction. The area  
12 under the receiver operating characteristics curve (AUC) for the A-ECG scores was calculated  
13 and the entire data set subsequently bootstrapped 2000 times to determine cross-validated  
14 diagnostic accuracy and obtain 95% confidence intervals (CI)<sup>13</sup>. The Youden index was used  
15 to optimise cut-offs for the specificity and sensitivity for each score to detect diastolic  
16 dysfunction<sup>13, 19</sup>. The A-ECG score was then used to estimate the probability of any subject in  
17 the study cohort having diastolic dysfunction, with cut-off predicted probability of >0.5. The  
18 score calculated the likelihood of having diastolic dysfunction from the logistic regression as:

19

20 Student's *t* test was used to compare the mean values of A-ECG measures between cohorts. A

### *Likelihood of diastolic dysfunction*

$$= \frac{1}{1 + e^{-(\text{coefficient}_1 \times \text{parameter}_1 + \text{coefficient}_2 \times \text{parameter}_2 \dots + \text{adjusted constant})}} \times 100$$

21 p-value <0.05 was considered statistically significant.

22

23

## 1 **Results**

### 2 ***Study Population***

3           The population considered consisted of 414 patients with baseline characteristics  
4 presented in Table 1. There were 264 patients with normal diastolic function and 150 with  
5 diastolic dysfunction (133 with grade 2 and 17 with grade 3 diastolic dysfunction). In the  
6 normal diastolic function group, 45% were males and mean age was  $62.1 \pm 9.1$  years. In the  
7 diastolic dysfunction group, 35% were males and mean age was  $76.7 \pm 9.4$  years. For purposes  
8 of subgroup analysis, the full cohort was also divided into an age-matched sub-cohort  
9 consisting of normal diastolic function (n=100) and diastolic dysfunction (n=100). The mean  
10 ages of the age-matched cohorts did not differ ( $71.8 \pm 4.8$  vs  $72.0 \pm 7.7$  years,  $p=0.89$ ). The  
11 study excluded patients with LVEF  $<55\%$ . A-ECG scores previously validated for the  
12 detection of reduced LVEF were also applied to this cohort, confirming a low likelihood of  
13 left ventricular systolic dysfunction for both the control and diastolic dysfunction cohorts (7  
14 [3–18] % and 13 [4–33] %, respectively), where a probability of  $>50\%$  was considered a high  
15 likelihood.

### 16 ***6-measure A-ECG score including age***

17           Standard feature selection based on stepwise logistic regression were used for  
18 constructing an A-ECG score for diastolic dysfunction. The optimal score ultimately  
19 contained six measures, with the two measures contributing most strongly to the score being  
20 age and the Cornell voltage product. The full list of measures is detailed in Table 2. This  
21 optimal 6-measure score provided excellent discrimination (AUC 0.91 [0.88-0.94]), see Table  
22 3. Figure 2 shows representative ECGs from two patients with high and low probabilities for  
23 diastolic dysfunction, respectively, by the A-ECG score. Table 4 compares the A-ECG  
24 measures between the normal and diastolic dysfunction cohort.

### 25 ***6-measure A-ECG score without P-wave components***

1 A 6-measure A-ECG score that did not include any P-wave components was also  
2 created and displayed a negligibly lower diagnostic performance for identifying diastolic  
3 dysfunction (AUC 0.91 [0.87-0.93]). The details of this score are also detailed in Table 3.

#### 4 *Age-independent analysis*

5 To better understand the effect of age on the 6-measure A-ECG scores, another, less  
6 optimal score was also ultimately created using purely A-ECG-derived variables, excluding  
7 age. Ten rather than six measures were necessary for this score to best compensate for the  
8 lack of inclusion of the most powerful measure of age. This 10-measure score ultimately  
9 included four A-ECG measures from the 6-measure score, and six additional A-ECG  
10 measures. The measures included in this score, and its diagnostic performance in both the full  
11 cohort and the age-matched sub-cohort, are presented in Tables 2 and 3, respectively. Figure 3  
12 illustrates the comparative receiver operating characteristics curves for the performance of the  
13 optimal 6-measure score in the full cohort, and the 10-measure score in both the full and age-  
14 matched cohorts, respectively. The 10-measure score had similar diagnostic performance to  
15 age in isolation when applied to the full cohort (AUC: 0.85 [0.81-0.89] vs 0.87 [0.82-0.90],  
16 respectively). The full diagnostic performance is detailed in Table 3.

#### 17 *Heart Age*

18 Heart age and heart age gap in the full and age-matched cohorts, respectively, are summarised  
19 in Figure 4. Compared to the group without diastolic dysfunction, the heart age gap was  
20 greater in the diastolic dysfunction group in both the full cohort ( $14.5 \pm 10.4$  vs  $10.7 \pm 8.5$  years,  
21  $p < 0.001$ ) and the age-matched cohort ( $14.8 \pm 10.1$  vs  $9.9 \pm 9.4$  years,  $p = 0.001$ ). Heart age gap  
22 alone demonstrated a modest predictive ability in identifying diastolic dysfunction when  
23 applied to our whole cohort (AUC 0.62 [0.56–0.68]). A weak correlation was demonstrated  
24 between heart age gap and our optimal 6-measure A-ECG score for diastolic dysfunction  
25 ( $R^2 = 0.05$ ,  $p < 0.001$ ).



## 1 **Discussion**

2           This study is the first to investigate the utility of A-ECG as a potential screening tool  
3 for diastolic dysfunction. Its major finding is that a 6-measure A-ECG score derived from a  
4 routine 12-lead ECG can identify diastolic dysfunction with clinically acceptable diagnostic  
5 performance. In addition to its diagnostic accuracy, our reported likelihood ratios demonstrate  
6 the utility of A-ECG analysis on an individual level independent of the prevalence of diastolic  
7 dysfunction in the population being studied. We have additionally chosen to report the inverse  
8 negative likelihood ratio as it helps illustrate the utility of a negative result following A-ECG  
9 testing expressed in a magnitude comparable to the positive likelihood ratio. For example, the  
10 optimal 6-measure score's inverse negative likelihood ratio of 5.12 suggests that following a  
11 negative A-ECG result, a patient is 5.12 times less likely to be diagnosed with diastolic  
12 dysfunction on TTE. Overall, these results suggest that A-ECG shows promise as a low-cost  
13 screening tool for identifying diastolic dysfunction and as a potential early-prevention  
14 measure for HFpEF.

## 15 **Validity and feasibility of A-ECG analyses**

16           When considering our results, it's important to consider the validity and feasibility of  
17 A-ECG as a technique for assessing disease. The introduction of the ECG in 1902 provided,  
18 for the first time, objective information about the electrical activity and function of the heart  
19 that could subsequently be used to diagnose a number of cardiac pathologies such as atrial  
20 fibrillation and myocardial infarction<sup>20,21,22</sup>. However, it was only in the 1960s that a  
21 multivariable approach to the conventional ECG was applied to improve diagnostic detection  
22 of diseases such as LV hypertrophy and prior myocardial infarction<sup>23,24</sup>. A-ECG is an  
23 extension of this arc of development, and is an emerging technology able to extract sufficient  
24 information from a standard resting 12-lead ECGs for the detection of a large range of cardiac  
25 pathologies<sup>10</sup>. It has been shown to improve diagnostic accuracy when compared to

1 conventional ECG in coronary artery disease, cardiomyopathies, LV hypertrophy and LV  
2 systolic dysfunction<sup>10, 13, 14</sup>.

3 To date, there is no widely accepted ECG-based method for detecting diastolic  
4 dysfunction. A machine learning model using clinical and ECG variables has shown potential  
5 to detect diastolic dysfunction with an AUC of 0.80 in an external test cohort<sup>7</sup>. However, that  
6 model relied on inclusion of a range of information including clinical co-morbidities such as  
7 hypertension and dyslipidaemia that may limit its applicability as a screening tool wherever  
8 such information is not readily available. A single-lead ECG recorded with specialised  
9 dedicated hardware and sampling rate far exceeding routine clinical ECG for 3 minutes has  
10 also been able to achieve high diagnostic accuracy for detecting diastolic dysfunction<sup>8</sup>.  
11 However, a major barrier for its widespread use as a routine screening tool on large  
12 populations is the need for dedicated equipment. By comparison, A-ECG analysis can be  
13 performed on a digital raw data file from a standard, 10-second, 12-lead ECG recorded using  
14 existing standard-fidelity ECG devices<sup>10</sup>.

15 The Cornell product was the single best performing A-ECG measure for the prediction  
16 of diastolic dysfunction. This is consistent with prior research which suggests that an  
17 increased Cornell product could be used to help diagnose diastolic dysfunction and was a  
18 marker of poor prognosis<sup>25</sup>. Similarly, QTc prolongation was a significant predictor of  
19 diastolic dysfunction in our cohort, which is in keeping with prior research. This is believed to  
20 be related to the close temporal relationship between QT interval and the diastolic period of  
21 the cardiac cycle<sup>26</sup>.

22 As such, the current study shows that the use of A-ECG techniques for detecting  
23 diastolic dysfunction achieves excellent diagnostic performance with methods that are  
24 economically and logistically feasible for widespread use. Furthermore, A-ECG can be  
25 performed rapidly and inexpensively using a standard 12-lead resting ECG while at the same

1 time also diagnosing or screening for other pathologies. Moreover, it's likely that many  
2 patients at risk of having or developing diastolic dysfunction would have pre-existing resting  
3 12-lead ECGs from the past for convenient retrospective analysis.

4

## 5 **Age and diastolic dysfunction**

6 Age and sex were the only non-ECG measures considered in the multivariable  
7 analysis, both comprising readily available information at the time of ECG data collection that  
8 do not rely upon access to laboratory or other detailed clinical information or history. While  
9 sex was not retained in the final model, age was the measure with the highest magnitude of  
10 contribution to the multivariable logistic regression for the optimal score (Table 2).

11 This is consistent with our current understanding of the pathogenesis of diastolic dysfunction  
12 and HFpEF. Similarly, the mean age of patients in our diastolic dysfunction cohort was higher  
13 than that in our normal diastolic function control group, albeit with sizable overlap ( $77\pm 9$  vs  
14  $62\pm 9$  years). For reference the AUC of age in isolation was 0.87 [0.82-0.90]. The addition of  
15 A-ECG measures to the 6-measure score further increased the AUC to 0.91[0.88-0.94],  $p$   
16  $<0.001$ ). A comparison performed by deriving a 10-measure score consisting of purely A-  
17 ECG parameters while excluding age showed that A-ECG components provided significant  
18 diagnostic information beyond age alone. A 10-measure score with only A-ECG measures  
19 and without age achieved very good diagnostic performance in the full cohort. Overall, it had  
20 a slightly lower AUC compared to the optimal 6-measure score (0.85 vs. 0.91) (Figure 3).  
21 Notably, 4 A-ECG measures from the optimal 6-measure score were also retained within the  
22 10-measure score, underscoring the general robustness of the A-ECG measures in the 6-  
23 measure score. Age-related ECG changes are well known, including prolongation of P-wave  
24 and QT intervals<sup>11</sup>. Therefore, it was important to determine whether or not the performance  
25 of the 10-measure score is driven by the ability to predict age as opposed to diastolic

1 dysfunction per se. As such, the performance of the 10-measure score was evaluated in an  
2 age-matched sub-cohort to ensure it was identifying diastolic dysfunction as opposed to  
3 advanced age. The preserved diagnostic accuracy of the 10-measurescore in the age-matched  
4 cohort (AUC 0.83) confirms that the A-ECG measures in this score associate with diastolic  
5 dysfunction and not just age alone. Taken together, the results of these additional analyses  
6 underscore that the 6-measure score can be used to accurately diagnose diastolic dysfunction.  
7 Heart age gap was increased in patients with diastolic dysfunction in both the full and age-  
8 matched cohorts. This also indicates that A-ECG analysis can detect ECG changes both  
9 beyond age and independent of age, which differ between cohorts. It is worth noting that  
10 while patients without diastolic dysfunction had a lower heart age gap than those with  
11 diastolic dysfunction, the heart age gap was still elevated to a level (approximately +10 years)  
12 that was on average near the upper limit of normal for previously described, low-risk healthy  
13 volunteers (approximately +12 years)<sup>10</sup>. This likely reflects the greater burden of  
14 cardiovascular risk factors and co-morbidities in our control group of patients referred to an  
15 outpatient cardiology clinic.

## 16 **Practical applications of A-ECG scores**

17 In the future, A-ECG may have application in a range of different clinical settings, in  
18 particular for primary care physicians where this novel information may allow for more  
19 accurate risk stratification for cardiac disease and assist in identifying only those patients who  
20 might most benefit from further cardiac imaging. In addition, the low skill and cost required  
21 to perform this analysis could provide significant value in population-based settings wherein  
22 relatively technically complex and expensive methods such as echocardiography might not be  
23 feasible. Another beneficial aspect of A-ECG is that it can simultaneously provide probability  
24 scores for a wide range of cardiac disease. Upon knowing the results of a transparently  
25 explainable numeric probability score available at the time of consultation, physicians may be  
26 better equipped to engage with patients regarding preventative therapy and lifestyle changes

1 to reduce the risk of developing cardiovascular disease. Diastolic dysfunction is under-  
2 diagnosed and a precursor to clinically overt HFpEF, the leading cause of heart failure<sup>27</sup>. As  
3 such, a low-resource screening tool for the diagnosis of diastolic dysfunction would be  
4 particularly valuable to aid early identification of individuals who might benefit from further  
5 cardiac assessment and risk factor modification to prevent or delay the development of  
6 HFpEF. Additional, fully prospective follow-on studies using the proposed optimal A-ECG  
7 score are therefore justified.

## 8 **Limitations**

9 The database used for this study had limited demographic information on patients, including a  
10 lack of information on the prevalence of cardiovascular risk factors such as diabetes and  
11 hypertension. Given that the control group was recruited from patients referred for outpatient  
12 cardiac assessment, it's also likely that this population contains a higher prevalence of cardiac  
13 co-morbidities than what would be expected from asymptomatic, healthy controls. It is also  
14 likely that even-age matched healthy controls would display an increased likelihood of  
15 diastolic dysfunction due to normal healthy ageing. Consequently, there is a potential that the  
16 reported accuracy of A-ECG analysis is underestimated and the use of fully asymptomatic  
17 healthy controls as a normal cohort would further increase the strength of our predictive  
18 model. However, our methodology and the wide inclusion criteria for both groups are closely  
19 reflective of real-world practice faced by clinicians who may use this technology.  
20 Additionally, our data were collected from a single outpatient cardiology practice. As such the  
21 score may not be as generalisable to populations which differ greatly from our cohort.

22 The utility of the score might also be limited in patients who fall outside of our study  
23 inclusion criteria, in particular patients younger than 50 years of age. However, it's worth  
24 noting that younger patients are less likely to be a target population for screening for diastolic  
25 dysfunction. Furthermore, only patients in sinus rhythm and without significant conduction  
26 disease were included in the study. Patients with atrial arrhythmia and/or ventricular

1 conduction disease, both prevalent in patients with diastolic dysfunction and heart failure,  
2 could therefore not currently be screened using our optimal A-ECG score. It would therefore  
3 be beneficial to develop additional, dedicated scores for patients with atrial fibrillation or  
4 advanced conduction disease in the future. Whilst this study did not include any patients in  
5 atrial fibrillation or flutter, our 6-measure score that excluded all measures from the P-wave  
6 also demonstrated excellent diagnostic accuracy (AUC 0.91 [0.87-0.93]). Whether this  
7 alternative score might therefore have diagnostic utility in patients with atrial arrhythmias  
8 remains to be ascertained. Finally, this was a single-center study, and both cross-validation  
9 and internal validation testing with an age-matched sub-cohort were used. The use of a  
10 separate, external validation cohort from a different centre would help provide further  
11 confidence in the generalisability of our findings.

12

### 13 **Conclusions**

14 A 6-measure score derived from A-ECG analysis of the conventional resting 12-lead  
15 ECG is able to detect diastolic dysfunction with high diagnostic accuracy. A-ECG shows  
16 potential as a screening tool for diastolic dysfunction, to potentially reduce the number of  
17 unnecessary echocardiographic examinations while facilitating early management of  
18 cardiovascular risk factors to help mitigate progression to HFpEF.

19

### 20 **Disclosures**

21 TTS is owner and founder of Nicollier-Schlegel SARL, which performs ECG interpretation  
22 consultancy using software that can quantify the advanced ECG measures used in the current  
23 study. TTS and MU are founders of Advanced ECG Systems, a company that is developing  
24 commercial applications of advanced ECG technology used in the current study. RK has a  
25 financial interest in Advanced ECG Systems through being married to MU.

## 1   **References**

- 2   1.       Nagueh SF. Left Ventricular Diastolic Function: Understanding Pathophysiology, Diagnosis,  
3   and Prognosis With Echocardiography. *JACC Cardiovasc Imaging*. 2020;13(1, Part 2):228-44.
- 4   2.       Borlaug BA, Kass DA. Invasive hemodynamic assessment in heart failure. *Cardiol Clin*.  
5   2011;29(2):269-80.
- 6   3.       Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, et al.  
7   Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An  
8   Update from the American Society of Echocardiography and the European Association  
9   of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29(4):277-314.
- 10  4.       Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022  
11  AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of  
12  Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*.  
13  2022;145(18):e895-e1032.
- 14  5.       Satpathy C, Mishra TK, Satpathy R, Satpathy HK, Barone EJ. Diagnosis and management of  
15  diastolic dysfunction and heart failure. *Am Fam Physician*. 2006;73(5):841-6.
- 16  6.       Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology,  
17  diagnosis, and treatment. *Eur Heart J*. 2010;32(6):670-9.
- 18  7.       Kagiyama N, Piccirilli M, Yanamala N, Shrestha S, Farjo PD, Casaclang-Verzosa G, et al.  
19  Machine Learning Assessment of Left Ventricular Diastolic Function Based on Electrocardiographic  
20  Features. *J Am Coll Cardiol*. 2020;76(8):930-41.
- 21  8.       Kuznetsova N, Gubina A, Sagirova Z, Dhif I, Gognieva D, Melnichuk A, et al. Left Ventricular  
22  Diastolic Dysfunction Screening by a Smartphone-Case Based on Single Lead ECG. *Clin Med Insights:*  
23  *Cardiol*. 2022;16:11795468221120088.
- 24  9.       Maanja M. Advanced Electrocardiography in Myocardial Electrical Remodeling-Insights from  
25  Cardiovascular Magnetic Resonance Imaging: Karolinska Institutet (Sweden); 2020.
- 26  10.      Schlegel TT, Kulecz WB, Feiveson AH, Greco EC, DePalma JL, Starc V, et al. Accuracy of  
27  advanced versus strictly conventional 12-lead ECG for detection and screening of coronary artery

- 1 disease, left ventricular hypertrophy and left ventricular systolic dysfunction. *BMC Cardiovasc Disord.*
- 2 2010;10(1):1-11.
- 3 11. Lindow T, Palencia-Lamela I, Schlegel TT, Ugander M. Heart age estimated using explainable
- 4 advanced electrocardiography. *Sci Rep.* 2022;12(1):1-10.
- 5 12. Schlegel TT, Kulecz WB, DePalma JL, Feiveson AH, Wilson JS, Rahman MA, et al. Real-time 12-
- 6 lead high-frequency QRS electrocardiography for enhanced detection of myocardial ischemia and
- 7 coronary artery disease. *Mayo Clin Proc.* 2004;79:339-50.
- 8 13. Maanja M, Schlegel TT, Kozor R, Lundin M, Wieslander B, Wong TC, et al. The electrical
- 9 determinants of increased wall thickness and mass in left ventricular hypertrophy. *J Electrocardiol.*
- 10 2020;58:80-6.
- 11 14. Johnson K, Neilson S, To A, Amir N, Cave A, Scott T, et al. Advanced electrocardiography
- 12 identifies left ventricular systolic dysfunction in non-ischemic cardiomyopathy and tracks serial
- 13 change over time. *J Cardiovasc Dev Dis.* 2015;2(2):93-107.
- 14 15. Batdorf BH, Feiveson AH, Schlegel TT. The effect of signal averaging on the reproducibility
- 15 and reliability of measures of T-wave morphology. *J Electrocardiol.* 2006;39(3):266-70.
- 16 16. KORS JA, VAN HERPEN G, SITTIG AC, VAN BEMMEL JH. Reconstruction of the Frank
- 17 vectorcardiogram from standard electrocardiographic leads: diagnostic comparison of different
- 18 methods. *European Heart Journal.* 1990;11(12):1083-92.
- 19 17. Wickham H. *Data analysis. ggplot2*: Springer; 2016. p. 189-201.
- 20 18. Wickham H, François R, Henry L, Müller K. *dplyr: A grammar of data manipulation. R package*
- 21 *version 04.* 2015;3:p156.
- 22 19. Youden WJ. Index for rating diagnostic tests. *Cancer.* 1950;3(1):32-5.
- 23 20. Howell JD. Diagnostic Technologies: X-Rays, Electrocardiograms, and CAT Scans. *S Cal L Rev.*
- 24 1991;65:529.
- 25 21. Lewis T. Report CXIX. Auricular fibrillation: a common clinical condition. *BMJ.*
- 26 1909;2(2552):1528.
- 27 22. Levine SA. Coronary thrombosis: its various clinical features. *Medicine.* 1929;8(3):245-418.



- 1 23. Pipberger HV, McCaughan D, Littmann D, Pipberger HA, Cornfield J, Dunn RA, et al. Clinical  
2 application of a second generation electrocardiographic computer program. *Am J Cardiol.*  
3 1975;35(5):597-608.
- 4 24. Kyle MC, Klingeman JD, Conrad JD, Freis ED, Pipberger HV. A new microcomputer-based ECG  
5 analysis system. *Clin Cardiol.* 1983;6(9):447-55.
- 6 25. Tan ES, Chan SP, Xu CF, Yap J, Richards AM, Ling LH, et al. Cornell product is an ECG marker of  
7 heart failure with preserved ejection fraction. *Heart Asia.* 2019;11(1):e011108.
- 8 26. Wilcox JE, Rosenberg J, Vallakati A, Gheorghiade M, Shah SJ. Usefulness of  
9 electrocardiographic QT interval to predict left ventricular diastolic dysfunction. *Am J Cardiol.*  
10 2011;108(12):1760-6.
- 11 27. van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH. Prevalence of  
12 unrecognized heart failure in older persons with shortness of breath on exertion. *European journal of*  
13 *heart failure.* 2014;16(7):772-7.
- 14
- 15

## 1 Tables

### 2 Table 1. Patient characteristics

Variable	Normal diastolic function	Diastolic dysfunction
Number of patients, n (%)	264 (64)	150 (36)
Male sex, n (%)	119 (45)	53 (35)
Age, years	62.1 ± 9.1	76.7 ± 9.4
Body surface area, m <sup>2</sup>	1.9 ± 0.2	1.8 ± 0.2
Echocardiographic data		
LA volume index, ml/m <sup>2</sup>	29.8 ± 8.0	45.2 ± 10.5
LV septal wall thickness, mm	9.4 ± 1.8	11.3 ± 2.1
LV posterior wall thickness, mm	9.1 ± 1.0	10.0 ± 2.2
E/A ratio	1.1 ± 0.4	1.1 ± 0.5
Average E/e' ratio	8.3 ± 2.3	14.9 ± 4.4
TR velocity, m/s	2.3 ± 0.3	2.8 ± 0.5
Peak E-Wave velocity, cm/s	71 ± 17	88 ± 21
Average e' velocity, cm/s	9.1 ± 2.6	6.3 ± 2.0
Septal e' velocity, cm/s	10.6 ± 3.2	7.1 ± 2.5
Lateral e' velocity, cm/s	7.6 ± 2.2	5.7 ± 1.8

3

4 All data reported as mean ± standard deviation. All other values represent total number

5 (percent) of affected individuals. Abbreviations: BSA = body surface area; E/e' = E to septal

6 e' velocity ratio; LA = left atrial; LV = left ventricular; TR = Tricuspid regurgitation.

7

**Table 2. A-ECG measures involved in the respective scores.**

ECG measures	6-measure A-ECG score			6-measure A-ECG score (without any P-wave components)			10-measure A-ECG score without age		
	Coefficient Estimate	Chi-square	p-value	Coefficient Estimate	Chi-square	p-value	Coefficient Estimate	Chi-square	p-value
Age, years	0.171924	90.1	< 0.001	0.175	95.0	<0.001	-	-	-
Cornell Product, mV*ms	0.013901	19.8	< 0.001	0.014	21.0	<0.001	-	-	-
P' amplitude in lead V3, uV	-0.079075	10.5	0.001	-	-	-	-0.112	13.1	< 0.001
Change of the QRS azimuth between five eighths to four eighths of the duration of the spatial QRS loop, degrees	0.015809	9.6	0.002	-0.017	10.9	<0.001	-0.013	9.7	0.002
Corrected QT interval, ms	0.017390	9.2	0.002	0.017	9.9	0.002	0.016	10.7	0.001
Minimum azimuth of the spatial QRS loop, sine radians	3.5621222	5.4	0.02	3.748	6.1	0.01	6.364	19.3	< 0.001
Net area subtended by the T wave in derived lead X, uV*ms	-	-	-	-	-	-	-4.505x10 <sup>-05</sup>	16.1	< 0.001
The slope of the ST segment in lead III, uV/s	-	-	-	1.626x10 <sup>-4</sup>	4.9	0.03	-	-	-
Cornell Voltage, mV	-	-	-	-	-	-	1.997	43.4	< 0.001
P' amplitude in lead aVR, uV	-	-	-	-	-	-	0.020	24.0	< 0.001
Magnitude of the ST-T segment six eighths of the way through the spatial ST-T loop, uV	-	-	-	-	-	-	0.007	21.8	< 0.001
5th singular value of the T wave, log uV	-	-	-	-	-	-	-1.436	12.2	< 0.001
R duration in lead I, ms	-	-	-	-	-	-	0.020	9.1	0.003
Intercept	-17.803501	-	-	-17.66	-	-	-2.394	-	-

**Table 3. Accuracies and Predictive Values of all calculated A-ECG Scores in the full study cohort and age-matched sub-cohort.**


A-ECG score	Cohort for testing	AUC	Sensitivity(%)	Specificity(%)	PPV (%)	NPV (%)	PLR	INLR
6 measures including age	Full	0.91[0.88-0.94]	83 [76-91]	87 [77-92]	78 [69-85]	90 [86-94]	6.38 [3.30-11.38]	5.12 [3.21-10.22]
6 measures including age, but without P-wave components	Full	0.91 [0.87-0.93]	81 [71-91]	87 [77-93]	78 [67-86]	89 [85-94]	6.23 [3.09-13.00]	4.58 [2.66-10.33]
10 measures without age	Full	0.85 [0.81-0.89]	73 [61-93]	83 [61-94]	72 [57-84]	85 [80-94]	4.29 [1.56-15.50]	3.07 [1.56-13.43]
10 measures without age	Age-matched	0.83 [0.77-0.88]	72 [56-86]	84 [68-94]	82 [71-92]	75 [67-84]	4.50 [1.75-14.33]	3.00 [1.55-6.71]
Age alone	Full	0.87[0.82-0.90]	83[68-91]	78[69-90]	68[61-80]	89 [83-93]	3.77 [2.19-9.10]	4.59 [2.16-10.00]

Full cohort (n=414), normal diastolic function (n=264) and diastolic dysfunction (n=150). Age-matched cohort (n=200), normal diastolic function (n=100) and diastolic dysfunction (n=100). Abbreviations: AUC = Area under curve; PPV = Positive predictive value; NPV = Negative predictive value; PLR = Positive likelihood ratio; INLR = Inverse of the negative likelihood ratio. Bracketed numbers are 95% confidence intervals derived from the bootstrap-related cross-validation procedure.



**Table 4. Comparison of A-ECG measures and age between patients with normal diastolic function and diastolic dysfunction (6 measure Score including P wave components).**

<b>Measure</b>	<b>Normal</b>	<b>Diastolic Dysfunction</b>	<b>P</b>
Age, years	62.1 ± 9.1	76.7 ± 9.5	<0.001
Cornell Product, mV*ms	112 ± 46	141 ± 63	<0.001
P' amplitude in lead V3, uV	-0.21 ± 3.5	-5.7 ± 19.8	<0.001
Change of the QRS azimuth between five eighths to four eighths of the duration of the spatial QRS loop, degrees	-45.5 ± 25	-25.5 ± 40.3	<0.001
Corrected QT interval, ms	422 ± 28	433 ± 27	<0.001
Minimum azimuth of the spatial QRS loop, sine radians	-0.95 ± 0.09	-0.93 ± 0.16	0.03

## Figures




**Figure 1. Flowchart describing study inclusion and exclusion criteria.** The selection criteria included patients referred for assessment at a large academic outpatient cardiology practice. The inclusion criteria included age >50, sinus rhythm, LVEF >55% and a recorded 12-lead ECG within 1 month of TTE. Patients were excluded if they had moderate or greater valvular disease, LVEF <55%, hypertrophic cardiomyopathy, valvular replacement, coronary bypass surgery, or any other cardiac procedures that required entering the pericardium. ECG abnormalities that would limit A-ECG analysis such as atrial arrhythmias, predominant ventricular ectopic beats and QRS duration >110ms were also excluded. Abbreviations: LVEF = Left ventricular ejection fraction; TTE = Transthoracic echocardiography.



Echocardiography measure	Patient A	Patient B
Diastolic dysfunction grade	Normal	Grade II
LAVI, ml/m <sup>2</sup>	28	42
E/A	0.75	0.86
Septal e', cm/s	6.7	4.5
Lateral e', cm/s	9.2	4.5
E/e'	6	25
TR Vmax, m/s	n/a	2.8


ECG Measure	Patient A	Patient B
Cornell Product, mV*ms	157	139
Minimum azimuth of the spatial QRS loop, sine radians	-0.999	-0.999
P' amplitude in lead V3, uV	0	-27
Change of the QRS azimuth between five eighths to four eighths of the duration of the spatial QRS loop, degrees	-64.2	-14.7
Corrected QT interval, ms	392	429
A-ECG Score for diastolic dysfunction	1%	99%

**Figure 2. Comparison of A-ECG results from the 12-lead ECGs of two representative patients.** Patient A has normal diastolic function with a corresponding low likelihood for diastolic dysfunction (10%) by A-ECG scoring. Patient B has diagnosed diastolic dysfunction with a high likelihood for diastolic dysfunction (98%) by A-ECG scoring.



**Figure 3. Comparisons of diagnostic performance for the 6-measure score in the full cohort, and the 10-measure score without age in the full and the age-matched cohort, respectively.**





**Figure 4: Heart age calculations in the full study cohort and age-matched sub-cohort.**

Heart age gap is defined as A-ECG heart age minus chronologic age. Full cohort (n=414), normal diastolic function (n=264) and diastolic dysfunction (n=150). Age-matched cohort (n=200), normal diastolic function (n=100) and diastolic dysfunction (n=100).